central hypersomnolence disorders narcolepsy
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients: - Definite narcolepsy type 1, narcolepsy type 2 or idiopathic hypersomnia, diagnosed according to the International Classification for Sleep Disorders - Third Edition (ICSD-3) criteria - Age between 18 and 65 years old - Normal or corrected-to-normal vision - Capacity to provide informed consent Healthy controls: - Age between 18 and 65 years old - Normal or corrected-to-normal vision - Capacity to provide informed consent
Exclusion criteria
Exclusion criteria: The following exclusion criteria will apply: - Systemic or neurological diseases (e.g., infections, inflammatory disorders, dementia, epilepsy); - Presence of another sleep-related disorder: For patients: Previous REM sleep behaviour disorder, insomnia, obstructive sleep apnoea, REM sleep behaviour disorder or Restless legs syndrome diagnosis according to the medical records For healthy controls: REM sleep behaviour disorder as screened by the Single-Question Screening for REM Sleep Behaviour Disorder Restless legs syndrome as screened by the Restless Legs Syndrome Screening Questionnaire (score > 6) High-risk for obstructive sleep apnoea according to the Stop-Bang questionnaire (score > 4) Insomnia disorder by the Insomnia Severity Index (score > 14) Circadian rhythm disorder - Short sleepers ( 65 years of age - Major psychiatric disorder (e.g., major depression, psychotic or bipolar disorder) - History of trauma capitis, encephalopathy, former intracranial surgery, alcoholism or substance abuse - Contraindications for MRI exam (e.g., claustrophobia, metallic implants)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We will aim at assessing non-invasive MRI-related neural biomarkers in narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia by comparing them with acutely sleep-deprived controls and healthy controls. To create a reliable and elaborate combination of possible markers, the following neuroimaging will be used: - Brain responses across the sleep-wake cycle using simultaneous EEG-fMRI - Brain responses during wakefulness using fMRI, especially in correlation with behavioral results in attentional and rewarded-associative memory tasks - Regional brain volumes and cortical thickness using MRI morphometry - White matter connectivity using DTI - Brain connectivity using structural covariance and resting-state fMRI functional connectivity - Regional GABA levels in the medial prefrontal cortex and posterior cingulate using MRS | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary analyses will include: - Correlation between neuroimaging activation maps and behavioral performance on the cognitive tasks. - Relationship between neuroimaging activation maps and clinical patient profiles (e.g. disease duration, subjective sleepiness and depression and anxiety scores) - Effect of sleep inertia on performance on the rewarded-associative memory task - The difference in molecular composition of exhaled breath between NT1, NT2 and IH and secondary in comparison to acutely sleep-deprived controls and HC - Effect of acute sleep deprivation on molecular exhaled breath composition in healthy controls As an exploratory objective, patients with idiopathic hypersomnia will be subcategorized in short ( 11 hours) sleepers and their neuroimaging profiles as defined in the primary objectives will be compared. | — |
Countries
Netherlands
Outcome results
None listed